Bosnia na Hezegovina - Kroeshia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - enalapril - tableta - 10 mg/1 tableta - 1 tableta sadrži: 10 mg enalaprilmaleata

Bosnia na Hezegovina - Kroeshia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - enalapril - tableta - 5 mg/1 tableta - 1 tableta sadrži; 5 mg enalapril maleata

Bosnia na Hezegovina - Kroeshia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zada pharmaceuticals d.o.o. - enalapril, hidrohlorotiazid - tableta - 10 mg/1 tableta+ 25 mg/1 tableta - 1 tableta sadrži: 10 mg enalaprilmaleat 25 mg hidrohlorotiazid

Bosnia na Hezegovina - Kroeshia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zada pharmaceuticals d.o.o. - enalapril, hidrohlorotiazid - tableta - 20 mg/1 tableta+ 12.5 mg/1 tableta - 1 tableta sadrži: 20 mg enalaprilmaleat 12,5 mg hidrohlorotiazid

Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - karbocistein - kapsula, tvrda - urbroj: jedna kapsula sadrži 375 mg karbocisteina

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

astellas pharma europe bv - takrolimus - odbacivanje transplantata - imunosupresivi - profilaksa odbacivanja transplantata kod odraslih primatelja bubrega ili jetrenih transplantata. liječenje odbacivanja alografta otpornih na liječenje drugim imunosupresivnim lijekovima u odraslih bolesnika.

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - takrolimus - odbacivanje transplantata - imunosupresivi - profilaksa odbacivanja transplantata kod odraslih primatelja bubrega ili jetrenih transplantata. liječenje odbacivanja alografta otpornih na liječenje drugim imunosupresivnim lijekovima u odraslih bolesnika.

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

krka, d.d., novo mesto - repaglinid - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - repaglinida indicirana je u bolesnika s dijabetesom tipa-2 (ne-inzulin šećerne bolesti (niddm)) čiji hiperglikemija više ne upravlja zadovoljavajući način prehrane, smanjenje težine i vježbe. repaglinid je također indiciran u kombinaciji s metforminom u bolesnika s dijabetesom tipa 2 koji nisu zadovoljavajući kontrolirani samo na metforminu. liječenje treba započeti što je dodatak prehrani i vježbe za snižavanje glukoze u krvi zbog obroka.

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

dechra regulatory b.v. - desoksikorton pivalat - kortikosteroidi za sistemsku upotrebu - psi - za korištenje kao nadomjesne terapije минералокортикоидной srca kod pasa s primarnim hypoadrenocorticism (addison bolest).